comparemela.com
Home
Live Updates
Adaptimmune Therapeutics PLC: Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company : comparemela.com
Adaptimmune Therapeutics PLC: Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelinPreclinical
Related Keywords
Pennsylvania ,
United States ,
Philadelphia ,
Canada ,
American ,
Dana Lynch ,
Ali Behbahani ,
Piper Sandler ,
David Mott ,
Garry Menzel ,
Andrew Allen ,
Adrian Rawcliffe ,
Priti Hegde ,
John Furey ,
Kristen Hege ,
Lawrence Alleva ,
Elliot Sigal ,
Julip Miller ,
Exchange Commission ,
Corporate Communications ,
Therapeutics Inc ,
Securities Exchange ,
United Newsfile Corp ,
Ropes Gray ,
Corporate Affairs ,
Goodwin Procter ,
Nasdaq ,
Chief Executive Officer ,
Nasdaq Stock Market ,
Securities Act ,
Securities Exchange Act ,
American Depositary Shares ,
Annual Report ,
Quarterly Reports ,
Senior Director ,
Adaptimmune ,
Herapeutics ,
Nnounces ,
Completion ,
Strategic ,
Combination ,
Ecr2 ,
Reating ,
Preeminent ,
Olid ,
Humor ,
Fell ,
Therapy ,
Company ,
comparemela.com © 2020. All Rights Reserved.